A carbazole donor compound and its synthesis method and application

By developing metal-free pure organic carbazole donor compounds, the problems of inorganic materials' metabolism difficulties and insufficient modification of organic materials were solved, and near-infrared two-zone molecules suitable for photothermal/photodynamic combination therapy were prepared, and the Effective tumor treatment at the living level.

CN117229299BActive Publication Date: 2024-11-01WUYI UNIV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202311101435.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-29
Publication Date
2024-11-01
Estimated Expiration
2043-08-29

AI Technical Summary

Technical Problem

Inorganic materials in existing phototherapy materials are difficult to be effectively used for tumor treatment at the living level due to their difficulty in metabolism and high toxicity. Although organic materials have good biocompatibility, they lack modification ability and large-scale production capacity.

Method used

Develop a metal-free pure organic carbazole donor compound to prepare near-infrared two-zone molecules through specific structural design and synthesis methods, with modification, low toxicity and good metabolic ability, and applied to light through nanocompounds Thermal/photodynamic combined therapy.

Benefits of technology

It has achieved metal pollution-free, low toxicity and good biocompatibility, and has adjustable photothermal and photodynamic properties. It is suitable for combined photothermal/photodynamic treatment, showing excellent anti-tumor performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004423268530000011
    Figure BDA0004423268530000011
  • Figure BDA0004423268530000012
    Figure BDA0004423268530000012
  • Figure BDA0004423268530000021
    Figure BDA0004423268530000021
Patent Text Reader

Abstract

The invention discloses a carbazole donor compound and a synthesis method and application thereof, and the material prepared by the compound has strong modifiability, low toxicity, excellent biocompatibility and good metabolic capacity. The near-infrared zone II molecule of the invention eliminates the problems of metal pollution and toxicity. Secondly, the molecule has strong modifiability and can be adjusted and optimized by changing the structure of the π bridge or the electron acceptor to form a novel near-infrared zone II molecule of D-π-A-π-D structure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic functional materials, in particular to a carbazole donor compound and a synthesis method and application thereof. Background Art

[0002] As a medical problem that has not yet been solved, tumors seriously threaten human health. Their treatment has developed into an important research topic in the field of biomedicine today. Phototherapy is considered to be an alternative method for traditional tumor treatment due to its advantages such as non-invasiveness, low toxicity, and low drug resistance. Among them, photothermal therapy (PTT) has attracted much attention due to its short treatment time, obvious therapeutic effect, high specificity, precise spatiotemporal selectivity, and small side effects on the human body. Photodynamic therapy (PDT) uses photosensitizers to produce reactive oxygen species (ROS) with killing effects through photochemical reactions under a specific wavelength laser to exert therapeutic effects. It has significant advantages such as non-invasiveness, strong controllable operation, and small toxic side effects. Material development is an important part of phototherapy. The current phototherapy materials mainly include organic and inorganic types. Inorganic materials are difficult to metabolize and have high toxicity, which is not conducive to tumor treatment at the living level. Organic materials have broad application prospects in living phototherapy due to their good biocompatibility, strong modifiability, and low toxicity.

[0003] Therefore, it is of great significance to develop an organic material for application in in vivo phototherapy. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a carbazole donor compound having the following general structural formula:

[0005]

[0006] In the formula, R1 includes an alkyl chain having 1 to 12 carbon atoms or a polyethylene glycol chain having 1 to 12 carbon atoms;

[0007] The Ar group is an electron-withdrawing group;

[0008] The π bridge is selected from any one of the following structural formulas:

[0009]

[0010] The embodiments according to the first aspect of the present invention have at least the following beneficial effects:

[0011] The present invention provides a novel near-infrared zone II molecule, which adopts metal-free pure organic materials, has strong modifiability, low toxicity, excellent biocompatibility and good metabolic capacity. The near-infrared zone II molecule of the present invention, the metal-free pure organic material eliminates the problems of metal pollution and toxicity. Secondly, the molecule has strong modifiability and can be adjusted and optimized by changing the structure of the π bridge or the electron acceptor. In addition, the molecule has low toxicity, good compatibility with organisms, and can be effectively metabolized.

[0012] In some embodiments of the present invention, R1 comprises tert-butyl.

[0013] When R1 is tert-butyl, tert-butyl carbazole is used as an electron donor, a benzene ring or thiophene is introduced as a π bridge, and benzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) (BBT) or selenadiazolo[3,4-f]benzo[c][1,2,5]thiadiazole (BTSe) is used as an electron acceptor. By directly conjugating the nitrogen atom of the electron donor carbazole with the π bridge, a new type of near-infrared second-zone molecule with a D-π-A-π-D structure is formed.

[0014] In some embodiments of the present invention, Ar is selected from any one of the following structural formulas:

[0015]

[0016] R2 is any one having a benzene ring or a thiophene group.

[0017] In some embodiments of the present invention, R3 is an alkyl chain having 1-12 carbon atoms.

[0018] In the second aspect of the present invention, a method for synthesizing the carbazole donor compound is provided, comprising the following steps:

[0019] S1. After mixing a carbazole compound, an organic boron reagent, a metallocene complex catalyst, and a base catalyst, 1,4-dioxane is added, and the mixture is reacted under a nitrogen atmosphere to obtain compound 2;

[0020] S2. Compound 2, a benzoheterocyclic compound, an alkaline reagent, and a phosphine ligand palladium catalyst are mixed and reacted to obtain compound 3;

[0021] S3. Compound 3, an acid catalyst and a metal reducing agent are reacted and then impurities are removed to obtain compound 4;

[0022] S4. Compound 4, an acid-binding agent and an oxidant are reacted and then impurities are removed to obtain compound 5.

[0023] In some embodiments of the present invention, in step S1, the carbazole compound includes 9-(4-bromophenyl)-3,6-di-tert-butyl-9h-carbazole.

[0024] In some embodiments of the present invention, in step S1, the organoboron reagent includes pinacol borate.

[0025] In some embodiments of the present invention, the metallocene complex catalyst includes 1,1′-bis(di-phenylphosphino)ferrocenepalladium chloride.

[0026] In some embodiments of the present invention, the base catalyst comprises potassium acetate.

[0027] In some preferred embodiments of the present invention, the molar ratio of the 9-(4-bromophenyl)-3,6-di-tert-butyl-9h-carbazole, the 1,1′-bis(di-phenylphosphino)ferrocenepalladium chloride, the potassium acetate and the 1,4-dioxane is 1:(0.05-0.30):(2-4):(0.15-0.30).

[0028] In some embodiments of the present invention, in step S1, the temperature of the mixing reaction is 90-120°C.

[0029] In some embodiments of the present invention, in step S1, the mixing reaction time is 12 to 24 hours.

[0030] In some embodiments of the present invention, in step S1, the mixing reaction further includes impurity removal, and the impurity removal steps include extraction, drying, concentration and column chromatography separation.

[0031] In some embodiments of the present invention, in step S2, the benzoheterocyclic compound includes one of benzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and selenadiazolo[3,4-f]benzo[c][1,2,5]thiadiazole.

[0032] In some embodiments of the invention, the alkaline agent comprises potassium carbonate.

[0033] In some embodiments of the present invention, the phosphine ligand palladium catalyst comprises tetrakistriphenylphosphine palladium.

[0034] In some preferred embodiments of the present invention, in step S2, the molar ratio of the compound 2, the 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and the tetrakistriphenylphosphine palladium is (2.2-4):1:(0.03-0.1).

[0035] In some preferred embodiments of the present invention, step S2 further includes a solvent.

[0036] In some embodiments of the present invention, in step S2, the solvent includes at least one of toluene and water.

[0037] In some preferred embodiments of the present invention, in step S2, the volume ratio of toluene to water is 4:1.

[0038] The solvent under the above solvent ratio can play a better dissolving effect.

[0039] In some embodiments of the present invention, in step S2, the temperature of the mixing reaction is 90-120°C.

[0040] In some embodiments of the present invention, in step S2, the mixing reaction time is 12 to 24 hours.

[0041] In some embodiments of the present invention, in step S2, the mixed reaction further includes impurity removal, and the impurity removal steps include extraction, drying, concentration, and column separation.

[0042] In some embodiments of the present invention, in step S3, the molar ratio of the compound 3 to the iron powder is 1:(10-40).

[0043] In some embodiments of the present invention, in step S3, the acid catalyst includes acetic acid.

[0044] In some embodiments of the present invention, the metal reducing agent comprises iron powder.

[0045] In some embodiments of the present invention, in step S3, the molar ratio of the compound 3, the acetic acid and the iron powder is 1:(1-10):(10-40).

[0046] In some embodiments of the present invention, in step S3, the reaction is carried out under a nitrogen atmosphere.

[0047] In some embodiments of the present invention, in step S3, the reaction temperature is 100°C

[0048] In some embodiments of the present invention, in step S3, the impurity removal step includes: filtering to remove iron powder, adding saturated sodium bicarbonate aqueous solution, extracting, drying, concentrating, and separating by column chromatography.

[0049] In some embodiments of the present invention, in step S4, the molar ratio of the compound 4, the triethylamine and the thionyl chloride is 1:(50-70):(100-140).

[0050] In some embodiments of the present invention, in step S4, the acid binding agent includes triethylamine.

[0051] In some embodiments of the present invention, the oxidant comprises one of thionyl chloride and selenium dioxide.

[0052] In some embodiments of the present invention, step S4 further includes a solvent, and the solvent includes dichloromethane.

[0053] In some embodiments of the present invention, in step S4, the reaction temperature is 45°C.

[0054] In some embodiments of the present invention, in step S4, the impurity removal includes extraction, drying, concentration, and column chromatography separation.

[0055] The synthesis process of the near-infrared binary molecule of the present invention is simple, the raw materials are cheap and readily available, and large-scale production can be carried out.

[0056] In the third aspect of the present invention, a nano compound is provided, wherein the raw materials for preparing the nano compound include the carbazole donor compound.

[0057] In some embodiments of the present invention, the method for preparing the nanocompound comprises: 2k The mixed solution is dissolved in tetrahydrofuran by ultrasonication, and then the mixed solution is quickly poured into water under ultrasonication, heated and stirred to remove tetrahydrofuran in the solution.

[0058] The fourth aspect of the present invention proposes the use of a nano compound in preparing raw materials for a photothermal / photodynamic combined therapy method.

[0059] Application of the novel carbazole donor near-infrared zone II organic material in photothermal / photodynamic combined therapy. The novel carbazole donor near-infrared zone II organic material has excellent photothermal and photodynamic properties and is applied in photothermal and photodynamic combined therapy, so that the material has good anti-tumor performance. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0061] Figure 1 is the UV-visible absorption spectrum of JX-1NPs prepared in Test Example 1.

[0062] Figure 2 is the fluorescence emission spectrum of JX-2NPs prepared in Test Example 1.

[0063] Figure 3 This is the temperature rise curve of JX-1NPs prepared in Test Example 1, with the highest temperature rising to 57°C.

[0064] Figure 4 This is the temperature rise curve of JX-2NPs prepared in Test Example 1, with the highest temperature rising to 57°C.

[0065] Figure 5 The singlet oxygen production ability of JX-1NPs and JX-2NPs prepared in Test Example 1 was indicated by the fluorescent probe method.

[0066] Figure 6 The JX-1NPs and JX-2NPs prepared in Test Example 1 were tested for their ability to generate hydroxyl radicals using a fluorescent probe method.

[0067] Figure 7 This is the reaction step of Example 1 and Example 2.

[0068] Figure 8 These are the reaction steps of Examples 3 to 6. DETAILED DESCRIPTION

[0069] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0070] Example 1: Synthesis of Compound JX-1:

[0071]

[0072] S1: Compound 9-(4-bromophenyl)-3,6-di-tert-butyl-9h-carbazole (1 g, 2.30 mmol), bipyraclostrobin (1.75 g, 6.91 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium chloride (168.30 mg, 0.23 mmol), and potassium acetate (678.20 mg, 6.91 mmol) were weighed in a 250 mL double-necked flask, and dry 1,4-dioxane was added. The mixture was reacted at 100° C. under a nitrogen atmosphere for 12 hours. After the reaction was terminated, the mixture was extracted, dried, concentrated, and separated by column chromatography to obtain 0.90 g of white powder compound 2 with a yield of 81%. 1 H NMR (500MHz, Chloroform-d) δ8.13(d,J=1.9Hz,2H),7.70(d,J=8.5Hz,2H),7.49-7.40(dd,4H),7.31(d,J=8.7Hz,2H),1.58(s,18H),1.46(s,12H);

[0073] S2: Compound 2 (498.42 mg, 1.04 mmol), 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole (181.60 mg, 0.47 mmol), potassium carbonate (392.20 mg, 2.84 mmol), and tetrakistriphenylphosphine palladium (54.70 mg, 0.04 mmol) were weighed in a 100 mL double-necked flask, and toluene:water (v / v, 4:1) was added. The mixture was reacted at 95°C under a nitrogen atmosphere. After the reaction was terminated, the mixture was cooled to room temperature, extracted, dried, concentrated, and separated by column chromatography to obtain 154.20 mg of orange-red powder compound 3 with a yield of 37%. 1 H NMR (500MHz, Chloroform-d) δ8.17 (d, J = 1.8Hz, 4H), 7.84 (s, 6H), 7.57-7.51 (m, 8H), 7.26 (s, 2H), 1.50 (s, 36H);

[0074] S3: Compound 3 (100 mg, 0.11 mmol) was weighed in a 50 mL double-necked bottle, acetic acid (8.60 mL) was added, and then iron powder (239.40 mg, 4.29 mmol) was added. The mixture was stirred at 100°C under a nitrogen atmosphere. After the reaction was terminated, the iron powder was removed by filtration, and saturated aqueous sodium bicarbonate solution was added. The mixture was extracted, dried, concentrated, and separated by column chromatography to obtain 39 mg of yellow powder compound 4 with a yield of 42%. 1 H NMR (500MHz, Chloroform-d) δ8.18(d,J=1.9Hz,4H),7.89–7.81(m,8H),7.56(d,J=8.6Hz,4H),7.51(dd,J=8.7,2.0Hz,4H),4.26(s,4H),1.50(s,36H);

[0075] S4: Compound 4 (88.30 mg, 0.10 mmol) was weighed in a 50 mL double-necked flask, and dry dichloromethane was added in an ice-water bath, followed by triethylamine (5 mmol, 0.36 mL), and the mixture was stirred continuously. Sulfoxide chloride (10 mmol, 1.4 mL) was slowly added dropwise, and the mixture was refluxed and stirred at 45°C. After the reaction was terminated, the mixture was extracted, dried, concentrated, and separated by column chromatography to obtain 26 mg of blue-green powder JX-1 with a yield of 29%. 1 H NMR (500 MHz, Chloroform-d) δ8.55 (d, J = 6.3 Hz, 4H), 8.18 (d, J = 2.0 Hz, 4H), 7.90 (d, J = 8.5 Hz, 4H), 7.62 (d, J = 8.6 Hz, 4H), 7.52 (dd, J = 8.6, 2.0 Hz, 4H), 1.50 (s, 36H). The specific reaction steps are as follows: Figure 7 shown.

[0076] Example 2: Synthesis of Compound JX-2:

[0077]

[0078] S1: Compound 9-(4-bromophenyl)-3,6-di-tert-butyl-9h-carbazole (1 g, 2.30 mmol), bipyraclostrobin (1.75 g, 6.91 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium chloride (168.30 mg, 0.23 mmol), and potassium acetate (678.20 mg, 6.91 mmol) were weighed in a 250 mL double-necked flask, and dry 1,4-dioxane was added. The mixture was reacted at 100° C. under a nitrogen atmosphere for 12 hours. After the reaction was terminated, the mixture was extracted, dried, concentrated, and separated by column chromatography to obtain 0.90 g of white powder compound 2 with a yield of 81%. 1 H NMR (500MHz, Chloroform-d) δ8.13(d,J=1.9Hz,2H),7.70(d,J=8.5Hz,2H),7.49-7.40(dd,4H),7.31(d,J=8.7Hz,2H),1.58(s,18H),1.46(s,12H);

[0079] S2: Compound 2 (498.42 mg, 1.04 mmol), 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole (181.60 mg, 0.47 mmol), potassium carbonate (392.20 mg, 2.84 mmol), and tetrakistriphenylphosphine palladium (54.70 mg, 0.04 mmol) were weighed in a 100 mL double-necked flask, and toluene:water (v / v, 4:1) was added. The mixture was reacted at 95°C under a nitrogen atmosphere. After the reaction was terminated, the mixture was cooled to room temperature, extracted, dried, concentrated, and separated by column chromatography to obtain 154.20 mg of orange-red powder compound 3 with a yield of 37%. 1 H NMR (500MHz, Chloroform-d) δ8.17 (d, J = 1.8Hz, 4H), 7.84 (s, 6H), 7.57-7.51 (m, 8H), 7.26 (s, 2H), 1.50 (s, 36H);

[0080] S3: Compound 3 (100 mg, 0.11 mmol) was weighed in a 50 mL double-necked bottle, acetic acid (8.60 mL) was added, and then iron powder (239.40 mg, 4.29 mmol) was added. The mixture was stirred at 100°C under a nitrogen atmosphere. After the reaction was terminated, the iron powder was removed by filtration, and saturated aqueous sodium bicarbonate solution was added. The mixture was extracted, dried, concentrated, and separated by column chromatography to obtain 39 mg of yellow powder compound 4 with a yield of 42%. 1H NMR (500MHz, Chloroform-d) δ8.18(d,J=1.9Hz,4H),7.89–7.81(m,8H),7.56(d,J=8.6Hz,4H),7.51(dd,J=8.7,2.0Hz,4H),4.26(s,4H),1.50(s,36H);

[0081] S4: Compound 4 (80 mg, 0.09 mmol) and selenium dioxide (25.5 mg, 0.23 mmol) were weighed in a double-necked bottle, and dry tetrahydrofuran was added. The mixture was refluxed at 100°C under a nitrogen atmosphere. After the reaction was terminated, the mixture was cooled to room temperature, concentrated, and separated by column chromatography to obtain 45.90 mg of blue-green powder JX-2 with a yield of 52%. 1H NMR (500 MHz, Chloroform-d) δ8.46 (d, J=8.4 Hz, 4H), 8.18 (d, J=1.8 Hz, 4H), 7.88 (d, J=8.5 Hz, 4H), 7.63 (d, J=8.6 Hz, 4H), 7.51 (dd, J=8.6, 2.0 Hz, 4H), 1.50 (s, 36H). The specific reaction steps are as follows: Figure 7 shown.

[0082] Example 3: Synthesis of Compound JX-3:

[0083]

[0084] In compound JX-3, the π bridge is selected from Ar is selected from

[0085] S1: 3,6-di-tert-butylcarbazole (500 mg, 1.79 mmol), 2-bromothiophene (350 mg, 2.15 mmol), trans-1,2-cyclohexanediamine (511 mg, 4.475 mmol), sodium tert-butoxide (258 mg, 2.685 mmol), and cuprous iodide (85.12 mg, 0.448 mmol) were weighed in a 100 mL double-necked flask, 1,4-dioxane was added, vacuumed, filled with nitrogen, ventilated three times, stirred at 125°C, refluxed overnight, and the reaction was monitored by TLC. After the reaction was terminated, it was cooled to room temperature, extracted three times, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain 563.5 mg of a white powder compound with a yield of 87%. 1H NMR(500MHz,Chloroform-d)δ8.11(d,J=2.5Hz,2H),7.49(dd,J=8.6,2.0Hz,2H),7 .39(d,J=9.2Hz,2H),7.34(dd,J=4.4,2.6Hz,1H),7.19-7.14(m,2H),1.47(s,18H).

[0086] S2: Compound S1 (500 mg, 1.38 mmol) was added to a 50 mL double-necked bottle, anhydrous tetrahydrofuran was added to dissolve, n-butyl lithium (0.7 mL, 1.66 mmol) was added dropwise at -78 °C under nitrogen protection, and the mixture was stirred for 30 min and then transferred to room temperature, and stirring was continued. The reaction was monitored by TLC. After the reaction was terminated, the mixture was extracted three times, dried over anhydrous sodium sulfate, and concentrated to obtain a colorless oily compound S2, which was directly carried out to the next step without column chromatography.

[0087] S3: Compound S2 (507.5 mg, 0.78 mmol) and 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole (100 mg, 0.26 mmol) and bistriphenylphosphine palladium dichloride (18.2 mg, 0.026 mmol) were weighed in a 100 mL double-necked flask, redistilled tetrahydrofuran was added, vacuumed, filled with nitrogen, ventilated three times, refluxed at 125°C overnight, and the reaction was monitored by TLC. After the reaction was terminated, it was cooled to room temperature, saturated potassium fluoride solution was added, diatomaceous earth was filtered, and the filter cake was washed with dichloromethane. Then it was extracted three times, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain 122.9 mg of purple powder compound 3, with a yield of 59%. 1 H NMR (500MHz, Chloroform-d) δ 8.12 (d, J = 1.9 Hz, 4H), 7.65-7.61 (m, 6H), 7.56 (dd, J = 8.7, 1.9 Hz, 4H), 7.32 (d, J = 4.0 Hz, 2H), 1.48 (s, 36H).

[0088] S4: Compound S3 (140 mg, 0.15 mmol) was weighed in a 100 mL double-necked flask, HAc (12 mL) was added, and then iron powder (248.2 mg, 4.5 mmol) was added. The mixture was evacuated, filled with nitrogen, stirred at 100°C, and the reaction was monitored by TLC. After the reaction was terminated, the iron powder was removed by filtration, and a saturated aqueous sodium bicarbonate solution was added to the filtrate, extracted, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain 86.6 mg of orange-yellow powder NO-1 with a yield of 66%. 1H NMR(500MHz,Chloroform-d)δ8.13(d,J=1.9Hz,4H),7.62(d,J=8.6Hz,4H),7.53(dd,J=8 .7, 2.0Hz, 4H), 7.49 (d, J = 3.8Hz, 2H), 7.33 (d, J = 3.7Hz, 2H), 4.62 (s, 4H), 1.48 (s, 36H).

[0089] S5: Compound S4 (100 mg, 0.113 mmol) and selenium dioxide (31.4 mg, 0.283 mmol) were weighed in a 50 mL double-necked bottle, and dry tetrahydrofuran was added. The mixture was evacuated, filled with nitrogen, and ventilated three times. The mixture was refluxed at 100°C and the reaction was monitored by TLC. After the reaction was terminated, the mixture was cooled to room temperature, concentrated, and separated by column chromatography to obtain 57.6 mg of khaki powder JX-3, with a yield of 53%. 1 H NMR(500MHz,Chloroform-d)δ9.22(d,J=4.2Hz,2H),8.16(d,J=1.9Hz,4H),7.75(d ,J=8.6Hz,4H),7.57(dd,J=8.6,1.9Hz,,4H),7.46(d,J=4.2Hz,2H),1.51(s,36H).

[0090] Example 4: Synthesis of Compound JX-4:

[0091]

[0092] In compound JX-4, the π bridge is selected from Ar is selected from The preparation method of this embodiment is the same as that of embodiment 3. The specific reaction steps are as follows Figure 8 shown.

[0093] Example 5: Synthesis of Compound JX-5:

[0094]

[0095] In compound JX-5, the π bridge is selected from Ar is selected from CAS: 1262727-09-2; The preparation method of this example is the same as that of Example 3. The specific reaction steps are as follows Figure 8 shown.

[0096] Example 6: Synthesis of Compound JX-6:

[0097]

[0098] In compound JX-6, the π bridge is selected from Ar is selected from CAS: 2196162-74-8; The preparation method of this embodiment is the same as that of embodiment 3. The specific reaction steps are as follows Figure 8 shown.

[0099] Test Example 1

[0100] Preparation of Nanomaterials:

[0101] The materials JX1 and JX-2 prepared in Examples 1 and 2 were prepared into nanoparticles JX-1NPs and JX-2NPs by nanoprecipitation method for subsequent photothermal and photodynamic performance tests.

[0102] Specific preparation method: weigh 1 mg JX-1, 10 mg DSPE-PEG 2k Ultrasonic dissolution was carried out in 10 ml tetrahydrofuran solution, and then the mixture containing JX-1 and DSPE-PEG was added under ultrasonic conditions. 2k The tetrahydrofuran solution was quickly added into 10 ml of water, heated and stirred at 40°C to remove the tetrahydrofuran in the solution, and the nano-solution JX-1NPs was obtained. JX-2NPs was prepared by a similar method.

[0103] UV-visible absorption and fluorescence emission spectra of JX-1NPs and JX-2NPs were tested (2×10 -5 M tetrahydrofuran solution, room temperature), the measured UV-visible absorption spectrum and emission spectrum are as follows Figure 1 and Figure 2 The data are summarized in Table 1.

[0104] Table 1 UV-visible absorption and fluorescence emission spectra of JX-1NPs and JX-2NPs

[0105] Compound Maximum UV-Vis absorption wavelength Emission wavelength JX-1NPs 706nm 914nm JX-2NPs 771nm 922nm

[0106] The photothermal and photodynamic properties of JX-1 and JX-2 are important indicators for evaluating the phototherapy performance of the two materials.

[0107] (1) Photothermal performance test of JX-1NPs and JX-2NPs

[0108] Under laser conditions, the photothermal properties of JX-1NPs and JX-2NPs were tested, such as Figure 3 and Figure 4 As shown, at 660nm laser (laser density 1W / cm 2 ) irradiated, the temperature of 300 μg / ml JX-1NPs can reach 58°C, and JX-2NPs can reach 58°C under 808 nm laser (laser density 1 W / cm 2) irradiation, the temperature can reach 58°C. The photothermal properties of the two nanomaterials are sufficient to induce tumor cell death, thereby exerting the photothermal therapeutic function of JX-1NPs and JX-2NPs.

[0109] (2) Photodynamic performance test of JX-1NPs and JX-2NPs

[0110] Under laser conditions, the photodynamic properties of JX-1NPs and JX-2NPs were tested, such as Figure 5 As shown in Figure 2, JX-1NPs and JX-2NPs were co-incubated with the singlet oxygen fluorescent probe SOSG. The experiment showed that as the co-incubation time increased, the fluorescence at 530nm gradually increased, indicating that the two materials have the ability to generate singlet oxygen. Figure 6 As shown in the figure, JX-1NPs and JX-2NPs were co-incubated with the hydroxyl radical fluorescent probe APF. As the co-incubation time increased, the fluorescence at 520nm gradually increased, indicating that both materials have the ability to generate hydroxyl radicals. The photodynamic therapy function of the material is exerted through the generation of singlet oxygen and hydroxyl radicals.

[0111] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A carbazole donor compound, characterized in that The compound has the following general structural formula; In the formula, R1 is selected from an alkyl chain having 1 to 12 carbon atoms or a polyethylene glycol chain having 1 to 12 carbon atoms; The π bridge is selected from any one of the following structural formulas: Ar is selected from any one of the following structural formulas: R3 is an alkyl chain having 1 to 12 carbon atoms.

2. A carbazole donor compound, characterized in that The compound has the following general structural formula:

3. A carbazole donor compound, characterized in that The compound has the following general structural formula:

4. A method for synthesizing the carbazole donor compound according to claim 1, characterized in that: The following steps are involved: S1. After mixing a carbazole compound, an organic boron reagent, a metallocene complex catalyst, and a base catalyst, 1,4-dioxane is added, and the mixture is reacted under a nitrogen atmosphere to obtain compound 2; S2. Compound 2, a benzoheterocyclic compound, an alkaline reagent, and a phosphine ligand palladium catalyst are mixed and reacted to obtain compound 3; S3. Compound 3, an acid catalyst and a metal reducing agent are reacted and then impurities are removed to obtain compound 4; S4. Compound 4, an acid-binding agent, and an oxidant are reacted and then impurities are removed to obtain compound 5; The structure of the compound 2 is: The structure of the compound 3 is: The structure of compound 4 is: In step S1, the carbazole compound is selected from 9-(4-bromophenyl)-3,6-di-tert-butyl-9h-carbazole; In step S1, the organoboron reagent is selected from pinacol diboron; the metallocene complex catalyst is selected from 1,1′-bis(di-phenylphosphino)ferrocenepalladium chloride; and the base catalyst is selected from potassium acetate; In step S2, the benzoheterocyclic compound is selected from one of benzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and selenadiazolo[3,4-f]benzo[c][1,2,5]thiadiazole; the alkaline agent is selected from potassium carbonate; and the phosphine ligand palladium catalyst is selected from tetrakistriphenylphosphine palladium; In step S3, the acid catalyst is selected from acetic acid; the metal reducing agent is selected from iron powder; in step S4, the acid binding agent is selected from triethylamine; and the oxidant is selected from one of thionyl chloride and selenium dioxide.

5. A nano compound, characterized in that: The raw material for preparing the nano compound includes the carbazole donor compound according to any one of claims 1 to 3.

6. Use of the nanocompound as claimed in claim 5 in preparing raw materials for a photothermal combined therapy method.

Citation Information

Patent Citations

  • Organic electroluminescent material and application thereof

    CN101445422A

  • Organic electroluminescent material containing thiophene and preparation method and application thereof

    CN103288812A

  • Organic compound with dimethylanthracene as core and application thereof

    CN106467543A

  • Near-infrared absorbers, near-infrared absorbing / blocking films, photoelectric devices, organic sensors, and electronic devices

    CN112500423A

  • Compound and application thereof

    CN113173935A